ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Biologically adaptive radiation oncology in oligometastatic and oligoprogressive disease: MR- and CBCT-guided adaptation, molecular imaging, dose painting, biomarkers, and AI.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligometastatic disease (OMD) and oligoprogression are clinically actionable states in which local treatment of limited tumour burden can prolong disease control for selected patients. Randomised phase II trials support metastasis-directed therapy (MDT), usually stereotactic body radiotherapy (SBRT/SABR), in several settings, but the effect is not uniform across tumour types. SABR-COMET and two non-small-cell lung cancer (NSCLC) trials showed progression-free or overall-survival gains, whereas NRG-BR002 did not improve progression-free or overall survival in newly oligometastatic breast cancer. In oligoprogression, CURB improved progression-free survival in NSCLC but not breast cancer. These divergent results make biological and treatment-context selection more important than lesion count alone. Biologically adaptive radiation oncology extends adaptation beyond setup correction by linking anatomy-of-the-day, molecular imaging, tumour phenotype, and response to target definition, dose, fractionation, and timing. This narrative review critically compares conventional image-guided SBRT, cone-beam CT (CBCT)-guided online adaptive radiotherapy, MR-guided online adaptive radiotherapy, PET/PSMA-guided planning, biology-guided radiotherapy, dose painting, and radiomics/AI. CBCT-guided adaptation is positioned as an increasingly available bridge between conventional image guidance and MR-guided adaptation. The practical value of MR guidance is greatest when soft-tissue visibility, motion, or daily organ-at-risk proximity would otherwise prevent safe ablative dosing; biology-guided delivery, biomarker-triggered adaptation, predictive AI, and radioligand-MDT combinations remain investigational. A clinical decision framework is proposed to separate approaches ready for routine use from selectively useful and research-only strategies.
Indexed as
Identifiers
42579243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.